American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Special Study Timeline and Updates

Thank you for all the comments and questions received to date. We would like to provide further clarification on the timeline and details of the special study.


  • Participation in this special study is required by all CoC accredited sites to fulfill Standard 5.7 (with the exception of Veterans Affairs, Department of Defense and pediatric facilities).
  • For Integrated Network Cancer Programs, data will need to be submitted for each facility in the network.
  • Participation in this study cannot count for credit toward Standard 1.9 (Clinical Trial Accrual).

Instructional Documents

  • An electronic version of the instructions will be sent via email late next week.
  • The physical copies of the instructions will be sent via USPS during the week of April 3. We anticipate the instructions documents will be delivered 1–2 weeks after shipment. 


  • Data collection for the special study will begin on April 17
  • The deadline to submit all patient data is July 17
  • There will be no deadlines within this 12-week period but we suggest that facilities use the first 2–3 weeks to determine eligibility for all 12 patients. 

Patient Selection

Twelve (12) patients total meeting inclusion criteria will be selected by the study team from each institution’s NCDB records. If a facility has less than 12 patients meeting inclusion criteria, those patients will be selected and the facility will not be penalized.


  • We will hold webinars regularly during the study for any questions or issues that come up. Reminders will be sent 1–2 days prior to each webinar.
  • We will hold one webinar prior to the study start date to help registrars familiarize themselves with the study and the web form.
  • This webinar will take place Tuesday, April 11, 11:00 am–12:00 noon (CST).
  • Call-in details for the webinar on 4/11/17 will be sent during the week of 4/3/17.

Data Entry and Access to Web Form

Access to the special study web form to enter data will be given to those with “hospital registrar” and “co-registrar” roles in Datalinks only.

IRB Approval

The Commission on Cancer does not require sites to receive IRB approval for this study. More information can be provided to sites needing justification, if necessary.


Send any questions to